Dr Michael Christie
Research Fellow in Molecular Pathology
Department of Clinical Pathology
217 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Abstract PS1-10-07: Progression free survival and exploratory endpoints from PALVEN: a phase 1b study of palbociclib, letrozole and venetoclax in ER and BCL2-positive metastatic breast cancer
DOI: 10.1158/1557-3265.sabcs25-ps1-10-072026
Journal article
TNF-⍺-mediated myeloid-instructed CD14 CD4 T cells are associated with poor survival in lung adenocarcinoma
DOI: 10.1016/j.xcrm.2026.1025932026
Journal article
Differences in mRNA expression of neuroinflammation-related genes in the temporal lobe of patients with drug-resistant focal epilepsy
DOI: 10.1002/epd2.702202025
Journal article
Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumors
DOI: 10.1186/s13073-025-01534-52025
Journal article
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.CCR-25-14492025
Other
Supplementary Table S2 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306181952020
Research grants (ARC, NHMRC, MRFF)
Evaluation of a Community-Led Nutrition and Lifestyle Program for Weight Loss and Metabolic Health: A Randomised Controlled Trial.
RECENT SCHOLARLY WORKS
2025
Other
Supplementary Table S3 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306181892025
Other
Supplementary Figure S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306182042025
Other
Supplementary Table S5 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.306181832025
Other
Supplementary Table S1 from Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial
DOI: 10.1158/1078-0432.30618201